AbCellera Biologics Inc. ABCL
At closeNov 4, 2026, 7:25 PM EST
After hours · Nov 4, 7:25 PM ET
- YTD
- +259.06%
- 1 year
- +152.16%
- Market cap
- 3.98B
- Revenue (ttm)
- 66.17M
- Profit margin
- -248.84%
- EPS (ttm)
- -0.54
- Shares out
- 324.05M
- Forward P/E
- -16.10
- YTD return
- +259.06%
- 1-year return
- +152.16%
- Volume
- 2.67M
- Avg volume
- 6.38M
- Open
- 12.33
- Previous close
- 12.18
- Day's range
- 11.53 – 12.54
- 52-week range
- 2.78 – 14.82
- Beta
- 1.59
- Analysts
- Strong Buy
- Price target
- 17.17 (+39.8%)
- Earnings date
- Nov 9, 2026
3M +6.36 (+107.43%)
Key statistics
- Enterprise value
- 3.33B
- PEG ratio
- 0.00
- Price / sales
- 60.11
- Price / book
- 4.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -76.30%
- Free cash flow
- -46.43M
- Total cash
- 540.10M
- Total debt
- 135.62M
- Return on equity
- -17.30%
- Short % of float
- 12.16%
- 50-day average
- 12.31
- 200-day average
- 6.93
Analyst view
Consensus: strong buy
- Target (low)
- 9.00
- Target (mean)
- 17.17
- Target (high)
- 30.00
- Strong buy2
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.17762.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.17064 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.164 | -0.18 | -0.02 | -9.76% |
| May 11, 2026 | Mar 31, 2026 | -0.22 | -0.14 | +0.08 | +36.36% |
| Feb 24, 2026 | Dec 31, 2025 | -0.18 | -0.03 | +0.15 | +83.33% |
| Nov 6, 2025 | Sep 30, 2025 | -0.17 | -0.19 | -0.02 | -11.76% |
| Aug 7, 2025 | Jun 30, 2025 | -0.17 | -0.12 | +0.05 | +29.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | init | — | Buy |
| Sep 29, 2026 | JP Morgan | init | — | Overweight |
| Aug 11, 2026 | Truist Securities | main | Buy | Buy |
| Aug 6, 2026 | Stifel | main | Buy | Buy |
| Aug 6, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jul 7, 2026 | Benchmark | up | Hold | Buy |
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- abcellera.com
News
UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18 
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting 
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts 
JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17 - Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know 
AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause 
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
Your note
Sign in to keep a note on ABCL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOOTH ANDREW | Chief Financial Officer | Purchase | Aug 13, 2026 | 613,759 |
| HANSEN CARL L.G. | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 24, 2024 | 56,984,000 |
| HAYDEN MICHAEL REUBEN | Director | Purchase | Aug 23, 2026 | 0 |
| MONTALBANO JOHN S. | Director | Purchase | Aug 17, 2026 | 256,000 |
| THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 26, 2026 | 56,134,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 10.77% | 33,012,138 | 405.22M | Jun 29, 2026 |
| Capital World Investors | 4.43% | 13,588,349 | 166.80M | Jun 29, 2026 |
| Two Sigma Investments, LP | 3.40% | 10,437,431 | 128.12M | Jun 29, 2026 |
| TD Waterhouse Canada Inc. | 3.01% | 9,222,005 | 113.20M | Sep 29, 2026 |
| Bank of America Corporation | 2.00% | 6,141,539 | 75.39M | Jun 29, 2026 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.41% | 4,317,206 | 52.99M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 4.31% | 13,228,596 | 162.38M | Sep 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.63% | 1,945,418 | 23.88M | Sep 29, 2026 |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 0.41% | 1,257,977 | 15.44M | Aug 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.34% | 1,053,900 | 12.94M | Jun 29, 2026 |
| NORTHERN LIGHTS FUND TRUST III-Counterpoint Quantitative Equity ETF | 0.32% | 971,643 | 11.93M | Jun 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 0.29% | 877,500 | 10.77M | Sep 29, 2026 |